Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis.

"Conflict-of-interest statement: The authors deny any conflict of interest for this article."

"Author contributions: Zheng FY, Yang KS, Min WC, Li XZ, Xing Y, Zhang YS, and Zhao QC contributed to the conception and design of the study; Zheng FY, Yang KS, and Zhang YS contributed to the literature search and data extraction; Yang KS, Li XZ, and Xing Y contributed to risk of bias evaluation; Zheng FY, Yang KS, Zhang YS, and Zhao QC contributed to data analysis and interpretation; Zheng FY, Yang KS, Li XZ, Xing Y, Zhang YS, and Zhao QC wrote the first draft of the manuscript and edited the manuscript; all authors contributed to critical revision of the manuscript and approved the manuscript. As the co-first authors, Zheng FY and Yang KS have had the privilege of actively participating in every stage of the research process. From the initial conceptualization of the study to the finalization of the manuscript, Zheng FY and Yang KS have collaborated closely with fellow co-authors, exchanging ideas, refining methodologies, and interpreting results. Our collective efforts have resulted in a comprehensive and robust study, supported by a substantial body of evidence. Zheng FY and Yang KS have carefully analyzed the data, ensuring statistical rigor and validity. Furthermore, Zheng FY and Yang KS have critically evaluated the existing literature, drawing upon relevant studies to provide a solid foundation for the research. Zhang YS and Zhao QC as the co-corresponding authors of this article, expressed utmost support for the research presented in this study. Zhang YS and Zhao QC believe that the findings of this research will significantly contribute to the existing body of knowledge in our field. Furthermore, Zhang YS and Zhao QC have worked closely with a diverse team of experts from different institutions, disciplines, and backgrounds. Supported by National College Students Innovation and Entrepreneurship Training Program of Shenyang Pharmaceutical University, No. 202210163003."

"The current study was performed in accordance with the guidelines established by the Cochrane Collaboration[] and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement[]. The study was registered on the PROSPERO website under registration No. CRD42023451642[]."